MedTrace Logo

Interleukin-34 in Stage I and II Periodontitis

NCT06052774 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-09-28

No results posted yet for this study

Summary

Interleukin 34 (IL-34) is the second active component of (colony-stimulating factor receptor) CSF-1R. With regards to periodontal disease, It is debatable whether IL-34 is a pro-inflammatory cytokine (as seen in rheumatic arthritis and Sjogren syndrome) or an anti-inflammatory cytokine( as seen in Alzheimer's disease) so further studies could be conducted to better understand whether IL-34 is a proinflammatory or anti-inflammatory cytokine in the pathogenesis of periodontal diseases and to evaluate the change of its levels in Gingival crevicular fluid (GCF) in patients with periodontal disease after non-surgical periodontal therapy (NSPT).

Conditions

  • Cytokine Storm

Interventions

PROCEDURE

Non-Surgical periodontal therapy

Supra and Subgingival debridement for all patients except periodontally healthy individuals

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • hala A. Abuel Ela, Professor · Professor of Oral Medicine, Periodontology, Oral Diagnosis, Faculty of Dentistry, ASU

  • Doaa Adel-Khattab, Asso.Prof. · Associate Prof. of oral medicine, Periodontology and Oral diagnosis Faculty of dentistry ASU

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-07-01
Completion
2023-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06052774 on ClinicalTrials.gov